Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study

被引：0
|
作者：
Anna R. Schreiber
Jodi Kagihara
Megan Eguchi
Peter Kabos
Christine M. Fisher
Elisabeth Meyer
Elizabeth Molina
Lavanya Kondapalli
Cathy J. Bradley
Jennifer R. Diamond
机构：
[1] University of Colorado Anschutz Medical Campus,Department of Medicine
[2] University of Colorado Anschutz Medical Campus,Division of Medical Oncology
[3] University of Colorado Anschutz Medical Campus,School of Public Health, Department of Health Systems, Management, and Policy
[4] University of Colorado Anschutz Medical Campus,Department of Radiation Oncology
[5] University of Colorado Anschutz Medical Campus,Division of Cardiology
来源：
Breast Cancer Research and Treatment | 2022年 / 191卷
关键词：
Triple-negative breast cancer (TNBC); Adjuvant chemotherapy; Surveillance, Epidemiology, and End Results (SEER); Node-negative; Anthracycline;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：389 / 399
页数：10
相关论文
共 50 条
  • [1] Evaluating anthracycline plus taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
    Schreiber, Anna R.
    Kagihara, Jodi
    Eguchi, Megan
    Kabos, Peter
    Fisher, Christine M.
    Meyer, Elisabeth
    Molina, Elizabeth
    Kondapalli, Lavanya
    Bradley, Cathy J.
    Diamond, Jennifer R.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (02) : 389 - 399
  • [2] Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study
    Roy, Savannah
    Lakritz, Stephanie
    Schreiber, Anna R.
    Molina, Elizabeth
    Kabos, Peter
    Wood, Marie
    Elias, Anthony
    Kondapalli, Lavanya
    Bradley, Cathy J.
    Diamond, Jennifer R.
    EUROPEAN JOURNAL OF CANCER, 2023, 185 : 69 - 82
  • [3] Major adverse cardiovascular event outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
    Roy, S. C.
    Lakritz, S.
    Schreiber, A.
    Molina, E.
    Bradley, C.
    Kondapalli, L.
    Diamond, J. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S326 - S326
  • [4] Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study
    Roy, Savannah
    Lakritz, Stephanie
    Schreiber, Anna R.
    Kuna, Elizabeth Molina
    Bradley, Cathy J.
    Kondapalli, Lavanya
    Diamond, Jennifer R.
    EUROPEAN JOURNAL OF CANCER, 2024, 196
  • [5] Adjuvant chemotherapy with or without an anthracycline in older adults with node-negative triple-negative breast cancer (TNBC): A SEER Medicare study.
    Schreiber, Anna R.
    Kagihara, Jodi
    Eguchi, Megan
    Kabos, Peter
    Meyer, Elisabeth
    Kondapalli, Lavanya
    Fisher, Christine M.
    Bradley, Cathy J.
    Diamond, Jennifer Robinson
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Outcomes of African American (AA) versus caucasian (CA) women with triple-negative (TN) breast cancer following preoperative anthracycline and taxane-based chemotherapy
    Balmanoukian, A.
    Zhang, Z.
    Jeter, S. C.
    Tsangaris, T. N.
    Wolff, A. C.
    Armstrong, D. K.
    Fetting, J. H.
    Fackler, M.
    Gabrielson, E.
    Stearns, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis
    Guo, Sanxing
    Shi, Yonggang
    Lu, Shuo
    He, Yujie
    Jin, Guangyi
    Zhang, Suzhi
    Li, Xingya
    JOURNAL OF CANCER, 2020, 11 (22): : 6653 - 6662
  • [8] The role of CHFR as a predictive marker of response to taxane-based preoperative chemotherapy in triple-negative breast cancer
    Paplomata, Elisavet
    Sica, Gabriel
    Ehdaivand, Shahrzad
    Nickleach, Dana
    Liu, Yuan
    Zelnak, Amelia Bruce
    O'Regan, Ruth
    Brandes, Johann Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens
    Shusen Wang
    Yanxia Shi
    Zhongyu Yuan
    Xi Wang
    Donggen Liu
    Roujun Peng
    Xiaoyu Teng
    Tao Qin
    Jiewen Peng
    Guinan Lin
    Xiaomei Jiang
    Medical Oncology, 2012, 29 : 547 - 553
  • [10] Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens
    Wang, Shusen
    Shi, Yanxia
    Yuan, Zhongyu
    Wang, Xi
    Liu, Donggen
    Peng, Roujun
    Teng, Xiaoyu
    Qin, Tao
    Peng, Jiewen
    Lin, Guinan
    Jiang, Xiaomei
    MEDICAL ONCOLOGY, 2012, 29 (02) : 547 - 553
12345